The cancer therapy developer, which is commercialising research from University of Texas, has raised series B1 and B2 financing.
Immune-Onc Therapeutics, a US-based immuno-oncology therapy developer drawing on research from University of Texas, announced on Tuesday it has secured $73m in series B1 and B2 funding.
Investment management firm Oceanpine Capital led the round and was joined by Octagon Capital, Sphera Healthcare, Northern Light Venture Capital, Vivo Capital and Leukemia & Lymphoma Society’s Therapy Acceleration Program.
Founded in 2015, Immune-Onc is developing cancer immunotherapies intended to inhibit the infiltration of tumours and disrupt the suppression of patients’ immune systems.
The company’s lead drug candidate, IO-202, targets a type of blood-borne cancer known as acute myeloid leukaemia, and underwent a phase I trial in September 2020.
Immune-Onc secured the exclusive commercialisation rights for biotherapeutics from University of Texas Health Science Center at Houston and University of Texas Southwestern Medical Center in 2017. It will use the proceeds from the round to advance the development of its…
